Our Q2 2024 #earnings results are live. Check out our full $MRK financial summary and key highlights: merck.us/3Soe4nR

Join us today at 9 a.m. ET to learn more about our Q2 2024 #earnings: merck.us/2Tv6Nnq $MRK

#ByTheNumbers: Check out highlights from our Q2 2024 #earnings report: merck.us/3Wp73EO $MRK

Rob Davis, chairman and CEO, on our Q2 2024 #earnings: merck.us/3Wp73EO $MRK

Today, we announced the initiation of a Phase 3 trial in relapsed small cell #lungcancer, marking the start of the second pivotal study in our collaboration with Daiichi Sankyo US. Learn more: merck.us/3YtZC1M

Today, we announced that we’ve expanded our global development and commercialization agreement with Daiichi Sankyo US. Read more here: merck.us/4fvVO69

Learn more about our latest update in #oncology: merck.us/46F6GdV

Today, we announced the acquisition of a novel investigational bispecific antibody from Curon Biopharma. Learn how this further expands and diversifies our growing pipeline, with potential applications in B-cell malignancies and autoimmune diseases: merck.us/3yuXiwQ

Today, we’re proud to announce the European Commission’s approval of a new treatment option for #PulmonaryArterialHypertension (#PAH). Learn more: merck.us/4fWWIJ7

Read about our latest update in essential thrombocythemia here: merck.us/4dCLfwx

Learn more about our latest update in #oncology here: merck.us/47876JP

Learn more about our latest update in #bladdercancer: merck.us/4e5Efbw

Today, we announced the initiation of a Phase 2b/3 trial for patients with diabetic macular edema, a serious retinal condition that poses a risk to vision. Learn more: merck.us/3MDNWC9

We’re pleased to showcase new data across our diverse #oncology portfolio and pipeline at this year’s ESMO Congress in Barcelona. Learn more about our latest scientific research: merck.us/3ARzfsR

Today with Daiichi Sankyo US, we announced new Phase 2 data for our investigational #ADC in extensive-stage small cell #lungcancer. Learn more about the results here: merck.us/4cU5Xa9

We’re committed to advancing research to help patients with advanced #GastricCancer. Read about our latest Phase 3 #immunotherapy results here: merck.us/4d5zsG4

Today, we announced new Phase 3 data for our #immunotherapy in locally advanced #CervicalCancer. Learn more about the results here: merck.us/3MNMUDX

In collaboration with Eisai US, we presented new #oncology data in hepatocellular carcinoma, the most common type of #livercancer. Learn more about the results here: merck.us/3XrLnbv

We’re proud to present 10-years of follow up data for our immunotherapy in advanced #melanoma. Learn more about the late-breaking presentation: merck.us/3Tr5ZiU

Today, we shared new Phase 3 data from our #immunotherapy in early-stage triple-negative #breastcancer. Learn more about our unprecedented #TNBC results here: merck.us/3MLGkxO